SPORE in Prostate Cancer

前列腺癌中的孢子

• 批准号: 9752232
• 负责人: William J Catalona
• 金额: $ 212.67万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-18 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9752232
• 关键词: Address; Advocacy; Advocate; Affect; Aggressive course; Agonist; Algorithms; Androgens; Award; Bioinformatics; Biological Markers; Biology; Biometry; California; Cells; Chicago; Clinical; Clinical Trials; Collaborations; Combined Modality Therapy; Comprehensive Cancer Center; Core Facility; Data; Data Analyses; Data Collection; Development; Diagnosis; Disease; Disease Progression; Disease Resistance; Drug resistance; Early Diagnosis; EphB4 Receptor; Evolution; Failure; Funding; Future; Genetic Population Study; Genetic Transcription; Genotype; Gleason Grade for Prostate Cancer; Glucocorticoid Receptor; Group Meetings; Hormones; Human; Indolent; Innovative Therapy; Leadership; Light; Malignant Neoplasms; Malignant neoplasm of prostate; Medicine; Mentors; Molecular; Monitor; Outcome; Pathologist; Pathology; Pathway interactions; Patient-Focused Outcomes; Patients; Phase; Phase I Clinical Trials; Phosphotransferases; Population Sciences; Program Development; Prostate specific antigen measurement; Prostatic Neoplasms; Publications; Quality of life; Receptor Protein-Tyrosine Kinases; Research; Research Personnel; Research Project Grants; Resistance; Role; San Francisco; Scientist; Signal Pathway; Single Nucleotide Polymorphism Map; Solid Neoplasm; Specimen; Statistical Data Interpretation; TGF-beta type I receptor; Talents; Testing; Therapeutic; Time; Tissues; Transforming Growth Factor beta; Universities; Up-Regulation; Variant; Work; Xenograft procedure; anticancer research; cancer genetics; cancer recurrence; career; career development; castration resistant prostate cancer; clinical development; cohort; combinatorial; deprivation; design; experience; experimental study; genetic variant; improved; improved outcome; inhibitor/antagonist; innovation; leadership development; meetings; member; men; mouse model; new technology; novel; novel therapeutics; overtreatment; personalized medicine; phase I trial; pre-clinical; prevent; programs; prostate cancer progression; public health relevance; recruit; research and development; response; symposium; targeted treatment; therapeutic target; therapy resistant; transcriptome; translational cancer research; tumor; tumor heterogeneity; tumor progression; web site

DESCRIPTION (provided by applicant): This application is a request for funding of the SPORE in Prostate Cancer at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (RHLCCC), the University of Chicago Medicine Comprehensive Cancer Center (UCCCC), and NorthShore University HealthSystems (NS/UC), with contributions from the University of California San Francisco (UCSF), University of Southern California (USC) and University of Pittsburgh. We propose four projects: 1) Impact of germline genetic variants on failure of active surveillance for prostate cancer (Catalona, Witte, Brendler), 2) Glucocorticoid receptor antagonism in castration-resistant prostate cancer (Szmulewitz, Conzen), 3) EphB4 receptor kinase as a target in prostate cancer (Abdulkadir, Stadler), 4) Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancer (Yu, Kuzel). The four proposed projects refine our ability to detect lethal prostate cancer (Project 1), identify additional biomarkers for disease aggressiveness and response to targeted therapy in personalized medicine (Projects 1-4) and will improve therapy for castrate-resistant prostate cancer (Projects 2-4) in translational cancer research. The Core facilities (Administrative, Advocacy and Leadership Development, Biostatistics/Bioinformatics, Biospecimen Pathology) will support the development of the clinical trials, the analysis of data and the collection of blod and tissue specimens. Under the Administrative Core, SPORE investigators will be closely monitored and will continue to be highly interactive, meeting monthly in addition to holding small group meetings on a regular basis. The SPORE Internal and External Advisory Boards will offer guidance to the SPORE on a regular basis and the SPORE will support an Advocacy Group and both Developmental Research and Career Development Programs. Furthermore, the results obtained from SPORE studies will be made available to all cancer investigators in the RHLCCC, UCCCC and NS/UC through a variety of mechanisms including seminars, symposia, web site, publications etc. Finally, the Administrative Core introduces a Leadership Program that will mentor young investigators in developing their careers and becoming future SPORE cancer research leaders. All together, we anticipate that the results obtained through this SPORE Program will have a significant impact on patients affected by prostate cancer.

描述（由申请人提供）：本申请是对罗伯特H。西北大学Lurie综合癌症中心（RHLCCC）、芝加哥大学医学综合癌症中心（UCCCC）和北岸大学健康系统（NS/UC），以及加州弗朗西斯科大学（UCSF）、南加州大学（USC）和匹兹堡大学的贡献。我们提出四个项目：1）生殖系遗传变异对前列腺癌主动监测失败的影响（Catalona，Witte，Brendler），2）去势抵抗性前列腺癌中的糖皮质激素受体拮抗作用（Szmulewitz，Conzen），3）EphB 4受体激酶作为前列腺癌的靶点（Abdulkadir，Stadler），4）靶向FOXA 1下游通路：去势抵抗性前列腺癌的新治疗策略（Yu，Kuzel）。这四个拟议的项目完善了我们检测致命前列腺癌的能力（项目1）， 在个性化医疗中确定疾病侵袭性和对靶向治疗反应的其他生物标志物（项目1-4），并将在转化癌症研究中改善去势抵抗性前列腺癌的治疗（项目2-4）。核心设施（行政、宣传和领导力发展、生物统计学/生物信息学、生物标本病理学）将支持临床试验的开展、数据分析以及血液和组织标本的收集。在行政核心下，将密切监测SPORE调查员，并将继续保持高度互动，除了定期举行小组会议外，每月举行一次会议。SPORE内部和外部咨询委员会将定期向SPORE提供指导，SPORE将支持宣传小组以及发展研究和职业发展计划。此外，从孢子研究获得的结果将提供给所有癌症研究人员在RHLCCC，UCCCC和NS/UC通过各种机制，包括研讨会，座谈会，网站，出版物等最后，行政核心介绍了一个领导计划，将指导年轻的研究人员在发展自己的职业生涯，成为未来的孢子癌症研究的领导者。总之，我们预计通过该SPORE计划获得的结果将对前列腺癌患者产生重大影响。